Your browser doesn't support javascript.
loading
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Li, Qing; Jiang, Baishan; Guo, Jiaye; Shao, Hong; Del Priore, Isabella S; Chang, Qing; Kudo, Rei; Li, Zhiqiang; Razavi, Pedram; Liu, Bo; Boghossian, Andrew S; Rees, Matthew G; Ronan, Melissa M; Roth, Jennifer A; Donovan, Katherine A; Palafox, Marta; Reis-Filho, Jorge S; de Stanchina, Elisa; Fischer, Eric S; Rosen, Neal; Serra, Violeta; Koff, Andrew; Chodera, John D; Gray, Nathanael S; Chandarlapaty, Sarat.
Afiliación
  • Li Q; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jiang B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Guo J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Shao H; Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Del Priore IS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chang Q; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kudo R; Anti-Tumor Assessment, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Li Z; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Razavi P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Liu B; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Boghossian AS; Weill Cornell Medical College, New York, New York.
  • Rees MG; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ronan MM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Roth JA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Donovan KA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Palafox M; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Reis-Filho JS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • de Stanchina E; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Fischer ES; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Rosen N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Serra V; Anti-Tumor Assessment, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Koff A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chodera JD; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Gray NS; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chandarlapaty S; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Cancer Discov ; 12(2): 356-371, 2022 02.
Article en En | MEDLINE | ID: mdl-34544752
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas / Piridinas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Proteínas Inhibidoras de las Quinasas Dependientes de la Ciclina / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas / Piridinas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Proteínas Inhibidoras de las Quinasas Dependientes de la Ciclina / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article